In 1952 Conley and Hartmann described a unique coagulation inhibitor in two patients with systemic lupus erythematosus.1 This coagulation inhibitor, named lupus anticoagulant,2 refers to antibodies that prolong in vitro coagulation by interference with the binding of coagulation factors to phospholipid surfaces.3 The presence of lupus anticoagulant, however, is not specific for lupus as it has been described in healthy individuals, other autoimmune diseases, and in association with certain drugs, infections, and malignancies.47
Many studies have shown that lupus anticoagulant characterises a subset of lupus patients with high prevalences of thrombosis, fetal loss, and thrombocytopenia.4 5 840 It is still unknown whether Accepted for publication 27 lupus anticoagulant is only an epiphenomenon or whether it has a pathophysiological role in the development of thrombosis. Although there is a high prevalence of thromboembolic complications in patients with lupus anticoagulant,'1 12 some of these patients do not experience thrombotic manifestations. This raises the question whether there are thrombosis 'promoting' or 'protecting' factors in patients with lupus anticoagulant.
We have studied the interrelationship between the presence of lupus anticoagulant, the status of several haemostatic indices, and the presence of a history of thrombosis in a group of 74 patients with systemic lupus erythematosus and lupus-like disease. Knowledge of factors that contribute to or protect against thrombosis in patients with lupus anticoagulant is important both Lupus anticoagulant** 24 12 IgG ACA*t Low positive 16 19 Medium positive 7 3 High positive 3 1 IgM ACA Low positive 13 20 Medium positive 8 7 High positive 2 0 *p<0-05; **p<O.00l (X2 test).
tACA=anticardiolipin antibodies.
and prothrombin were determined in 36 lupus anticoagulant positive and 38 lupus anticoagulant negative lupus patients. For four patients taking oral anticoagulants protein C/prothrombin and protein S/prothrombin ratios were calculated. Concentrations of free protein S were measured in 65 patients, platelet counts in 64 patients, and bleeding times in 55 patients. Free protein S and bleeding time measurements were only performed in patients not using oral anticoagulants or non-steroidal antiinflammatory drugs respectively. The prevalence of low, medium, and high concentrations of anticardiolipin antibodies, as well as decreased, normal, and raised levels of all other coagulation indices were compared in patients with or without a history of thrombosis (Tables 1 and 3) (Tables  5 and 6 ).
The presence of decreased or increased concentrations of antithrombin III, plasminogen, total protein S, free protein S, protein C, or prothrombin were neither associated with a history of thrombosis nor with the presence of lupus anticoagulant (Tables  3 and 4 ). Except for total protein S, no significant differences in mean values were found for these variables between patients with or without thrombosis and between patients with or without lupus anticoagulant (Tables 5 and 6 ). The mean level of total protein S, determined in patients not taking oral anticoagulants, was significantly lower in patients with thrombosis than in those without thrombosis (Table 5 ) and in patients with lupus anticoagulant than in those without (Table 6) . A decreased platelet count (below 15Ox 109/l) was significantly associated with a history of thrombosis and with the presence of lupus anticoagulant (Tables  3 and 4) . Moreover, the mean platelet count of patients with a history of thrombosis was significantly lower than that of pateints without thrombosis (Table 5 ) and in patients with lupus anticoagulant than in those without (Table 6 ). Our data reconfirm the association between lupus anticoagulant and (mild) thrombocytopenia in lupus patients. Although we observed during follow up of individual patients that platelet counts in patients with lupus anticoagulant often vary from normal to mildly decreased, this cross sectional study clearly showed that thrombocytopenia occurred especially in patients with lupus anticoagulant and in association with a history of thrombosis. This suggests some form of 'higher turnover' coagulopathy in these patients. Our patients, however, did not have thrombosis at the time of study and mean platelet volumes were normal (data not shown), which contradicts this explanation.
The occurrence of a prolonged bleeding time in 38% of the patients could almost always be explained by defects in platelet function. The bleeding time of patients with lupus anticoagulant was significantly prolonged compared with patients without, but the tendency for a longer bleeding time in patients with a history of thrombosis than in those without was not statistically significant. The high incidence of a prolonged bleeding time in lupus patients in general, and in patients with lupus anticoagulant in particular, is remarkable because these patients do not suffer from bleeding manifestations.
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As this study is based upon single observations, one may wonder whether the values of the different variables tested fluctuate in time. Apart from common fluctuations in anticardiolipin antibody concentrations and platelet counts, we have never observed drastic changes in concentrations of the other plasma proteins, unless patients were receiving oral anticoagulants. Therefore, we have the impression that the conclusions drawn from this cross sectional study will be confirmed in future prospective, longitudinal studies to determine risk factors.
In conclusion, the presence of lupus anticoagulant, positive anticardiolipin antibody concentrations, a decreased (mean) protein S concentration, and a (mild) thrombocytopenia are significantly associated with a history of thrombosis in lupus patients. No such relation was found for decreased concentrations of antithrombin III, plasminogen, protein C, or free protein S. Decreased concentrations of prothrombin seem to protect against thrombosis. Analysis by stepwise logistic regression did not show additional risk factors for thrombosis in patients with lupus anticoagulant. Furthermore, increased antithrombin III concentrations, decreased free protein S concentrations, and a prolonged bleeding time are common findings in lupus patients, irrespective of the presence of lupus anticoagulant or a history of thrombosis, or both.
